Compatibility of C7 With Ketogenic Diet in Patients Diagnosed With G1D
Learn more about:
Related Clinical Trial
Ketonemia Through Menstrual Cycle
Brain Metabolism Observed at 7 Tesla
Diet Treatment Glucose Transporter Type 1 Deficiency (G1D)
Treatment Development of Triheptanoin (G1D)
Treatment Development for Glucose Transporter Type I Deficiency Syndrome (G1D)
Treatment With UX007 for a Single Patient With GLUT1 Deficiency Syndrome
Compatibility of C7 With Ketogenic Diet in Patients Diagnosed With G1D
Evaluation of Keyo in Children With Epilepsy
The Glucose Transporter Type I Deficiency (G1D) Registry
Evaluation of Ketoflo
Early Diagnosis of the GLUT1 Deficiency Syndrome With a Blood Based Test
Pilot Study of Triheptanoin in Patients With Glucose Transporter 1 Deficiency Syndrome
Evaluation of Krio in Children and Adults With Epilepsy
Post Study Continuation of C7 for G1D
Triheptanoin (C7 Oil), a Food Supplement, for Glucose Transporter Type I Deficiency (G1D)
Phase 2 Study of Triheptanoin (UX007) for the Treatment of Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS)
Phase II Open Label Study Using Triheptanoin in Patients With Glucose Type 1 Transporter Deficiency GLUT1-DS
An Open-Label Trial of Triheptanoin in Patients With Glucose Transporter Type-1 Deficiency Syndrome
Study to Assess the Long Term Safety and Efficacy of UX007 in Participants With Glucose Type 1 Deficiency Syndrome (Glut1 DS)
Crossover Study to Assess the Efficacy and Safety of UX007 in the Treatment of Movement Disorders Associated With Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS)
Sodium Lactate Infusion in GLUT1DS Patients